Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player
- ViiV turns to two-drug strategy to challenge HIV competition
- Share has kept growing despite new Gilead drug, ViiV CEO says
Photographer: Tomohiro Ohsumi/Bloomberg
This article is for subscribers only.
GlaxoSmithKline Plc’s HIV venture wants to use less burdensome forms of treatment to unseat rival Gilead Sciences Inc. and become the top player in the $26 billion-a-year market in the mid-2020s.
“If our pipeline and our competitors’ pipelines play out as we’re expecting, that’s our aim,” Deborah Waterhouse, chief executive officer of ViiV Healthcare, told journalists at a briefing Wednesday in London. “We believe we’ve got a strong pipeline to help us achieve that.”